Volume 15 Supplement 1

Proceedings of the International Cancer Imaging Society (ICIS) 15th Annual Teaching Course

Open Access

RECIST criteria: our experience in daily practice

  • S De Luca1Email author,
  • C Carrera1,
  • E Casalini Vañek1,
  • L Tolkachier1,
  • L Alarcon1 and
  • E Eyheremendy1
Cancer Imaging201515(Suppl 1):P31

https://doi.org/10.1186/1470-7330-15-S1-P31

Published: 2 October 2015

Learning objectives

Describe the utility and limitations of RECIST 1.1 criteria.

Emphasise the knowledge of complementary tools for the evaluation of response to treatment of solid tumours.

Content organisation

Our cases will be presented in a pictorial essay mode. Key differential diagnostic points will be highlighted in the discussion of each case.

It is important to consider:

Complete knowledge of clinical-oncologic status and treatments time points.

Recognition of smallest measured value (NADIR) between time points for adequate selection of comparative review.

Sum of target lesions (baseline and current time points) including percentage of change.

Select no more than two target lesions by sector.

Complete knowledge of actinic extension field which often could present different behavior than other lesional sites.

Local tumour growth over vital organs regardless strict RECIST criteria in exceptional cases.

Further criteria utilization in line with oncological disease being studied (mRECIST criteria for hepatocellular carcinoma or CHOI criteria for GIST).

Use of SUL on baseline PET CT studies with greater accuracy in assessing response on further evaluations (PERCIST criteria).

Conclusion

RECIST 1.1 proposes internationally accepted criteria to unify and standardise response to treatment of solid tumours in oncologic patients.

These criteria are reproducible but in some oncologic scenarios, we need to widen its use, due to the large number of treatment modalities and possible combined responses.

Authors’ Affiliations

(1)
Hospital Aleman

Copyright

© De Luca et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement